Oral Paricalcitol Versus Oral Calcitriol in Continuous Ambulatory Peritoneal Dialysis Patients with Secondary Hyperparathyroidism

Overview

Journal Clin Exp Nephrol

Publisher Springer

Specialty Nephrology

Date 2013 Aug 2

PMID 23903802

Citations 7

Authors

Ema J Jamaluddin

Abdul Halim Abdul Gafor

Loo Chee Yean

Rizna Cader

Rozita Mohd

Norella C T Kong

Shamsul Azhar Shah

Affiliations

Soon will be listed here.

Abstract

Background: Secondary hyperparathyroidism (SHPT) is common in end-stage renal disease. Our primary objective was to evaluate the efficacy of oral paricalcitol versus oral calcitriol on serum intact parathyroid hormone (iPTH) and mineral bone parameters in continuous ambulatory peritoneal dialysis (CAPD) patients with SHPT. The secondary objective was to analyze highly sensitive C-reactive protein (hsCRP) and peritoneal membrane function in both groups.

Methods: This was a prospective randomized control trial. CAPD patients with SHPT were randomized to paricalcitol or calcitriol for 15 weeks. Serum intact iPTH, calcium, phosphate and alkaline phosphatase (ALP) were measured at baseline and every 3 weeks. Serum hsCRP and peritoneal membrane functions were measured at baseline and at week 15.

Results: A total of 26 patients were enrolled and randomized-12 to paricalcitol and 14 to calcitriol. Serum iPTH reduced significantly in both groups and there was no difference in the incidence of ≥50 % reduction of iPTH between both groups. There was a significant increase in serum calcium in both groups but there were no differences in serum phosphorus across the visits. The incidence of hypercalcemia was the same in both groups. Serum calcium-phosphorus (Ca × P) product increased in the paricalcitol group but decreased in the calcitriol group. Serum ALP decreased significantly in both groups. There were also no differences in pre- and post-treatment serum hsCRP and peritoneal function test (PFT) in both groups.

Conclusion: Both oral paricalcitol and calcitriol were equally efficacious in reducing serum iPTH but were associated with significantly higher serum calcium. Serum Ca × P product increased in the paricalcitol group and decreased in the calcitriol group. Serum hsCRP level and PFT were not affected by either treatment. A larger randomized controlled trial is indicated to confirm these initial findings.

Citing Articles

Perirenal fat differs in patients with chronic kidney disease receiving different vitamin D-based treatments: a preliminary study.

Checa-Ros A, Locascio A, Okojie O, Abellan-Galiana P, DMarco L BMC Nephrol. 2025; 26(1):119.

PMID: 40045219 PMC: 11883930. DOI: 10.1186/s12882-025-04041-2.

Interaction of Vitamin D with Peptide Hormones with Emphasis on Parathyroid Hormone, FGF23, and the Renin-Angiotensin-Aldosterone System.

Latic N, Erben R Nutrients. 2022; 14(23).

PMID: 36501215 PMC: 9736617. DOI: 10.3390/nu14235186.

A comparative analysis of the efficacy and safety of paricalcitol versus other vitamin D receptor activators in patients undergoing hemodialysis: A systematic review and meta-analysis of 15 randomized controlled trials.

Geng X, Shi E, Wang S, Song Y PLoS One. 2020; 15(5):e0233705.

PMID: 32470067 PMC: 7259607. DOI: 10.1371/journal.pone.0233705.

Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis.

Liu Y, Liu L, Jia Y, Wu M, Sun Y, Ma F Drug Des Devel Ther. 2019; 13:999-1009.

PMID: 30992658 PMC: 6445244. DOI: 10.2147/DDDT.S176257.

Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials.

Xie Y, Su P, Sun Y, Zhang H, Zhao R, Li L BMC Nephrol. 2017; 18(1):272.

PMID: 28841848 PMC: 5574209. DOI: 10.1186/s12882-017-0691-6.

References

Block G, Klassen P, Lazarus J, Ofsthun N, Lowrie E, Chertow G . Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15(8):2208-18. DOI: 10.1097/01.ASN.0000133041.27682.A2. View

Izquierdo M, Cavia M, Muniz P, de Francisco A, Arias M, Santos J . Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients. BMC Nephrol. 2012; 13:159. PMC: 3520723. DOI: 10.1186/1471-2369-13-159. View

Goodman W, Goldin J, Kuizon B, Yoon C, Gales B, Sider D . Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000; 342(20):1478-83. DOI: 10.1056/NEJM200005183422003. View

Brown A, Finch J, Slatopolsky E . Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J Lab Clin Med. 2002; 139(5):279-84. DOI: 10.1067/mlc.2002.122819. View

Ganesh S, Stack A, Levin N, Hulbert-Shearon T, Port F . Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001; 12(10):2131-2138. DOI: 10.1681/ASN.V12102131. View

Chung S, Heimburger O, Stenvinkel P, Bergstrom J, Lindholm B . Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol Dial Transplant. 2001; 16(11):2240-5. DOI: 10.1093/ndt/16.11.2240. View

Martin K, Gonzalez E, Gellens M, Hamm L, Abboud H, Lindberg J . 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol. 1998; 9(8):1427-32. DOI: 10.1681/ASN.V981427. View

. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; (113):S1-130. DOI: 10.1038/ki.2009.188. View

Gafor A, Saidin R, Loo C, Mohd R, Zainudin S, Shah S . Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism. Nephrology (Carlton). 2009; 14(5):488-92. DOI: 10.1111/j.1440-1797.2008.01058.x. View

10.

Davies M, Hruska K . Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int. 2001; 60(2):472-9. DOI: 10.1046/j.1523-1755.2001.060002472.x. View

11.

Milliner D, Zinsmeister A, Lieberman E, LANDING B . Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int. 1990; 38(5):931-6. DOI: 10.1038/ki.1990.293. View

12.

Couttenye M, DHaese P, Van Hoof V, Lemoniatou E, Goodman W, Verpooten G . Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant. 1996; 11(6):1065-72. View

13.

Sprague S, Lerma E, McCormmick D, Abraham M, Batlle D . Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis. 2001; 38(5 Suppl 5):S51-6. DOI: 10.1053/ajkd.2001.28110. View

14.

Simonsen O, Venturoli D, Wieslander A, Carlsson O, Rippe B . Mass transfer of calcium across the peritoneum at three different peritoneal dialysis fluid Ca2+ and glucose concentrations. Kidney Int. 2003; 64(1):208-15. DOI: 10.1046/j.1523-1755.2003.00055.x. View

15.

Watson K, Abrolat M, Malone L, Hoeg J, Doherty T, Detrano R . Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation. 1997; 96(6):1755-60. DOI: 10.1161/01.cir.96.6.1755. View

16.

Block G, Levin N, Port F . Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998; 31(4):607-17. DOI: 10.1053/ajkd.1998.v31.pm9531176. View

17.

Ha S, Park C, Seo J, Park S, Kang S, Choi K . Studies on bone markers and bone mineral density in patients with chronic renal failure. Yonsei Med J. 1996; 37(5):350-6. DOI: 10.3349/ymj.1996.37.5.350. View

18.

Cozzolino M, Dusso A, Slatopolsky E . Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. J Am Soc Nephrol. 2001; 12(11):2511-2516. DOI: 10.1681/ASN.V12112511. View

19.

. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(4 Suppl 3):S1-201. View

20.

Parikh N, Hwang S, Larson M, Meigs J, Levy D, Fox C . Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med. 2006; 166(17):1884-91. DOI: 10.1001/archinte.166.17.1884. View